Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for CNS and orphan disorders and reduce the attrition rate in clinical development.
PsychoGenics is a Preclinical CRO with expertise in the CNS and orphan disorders. We are known for our cutting edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes, even early and subtle changes, that help our clients quantify the efficacy of their treatments before they move into the clinic.
With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, PsychoGenics enables clients to deliver superior clinical candidates.
The Company’s capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. Complementing its extensive capabilities, PsychoGenics offers a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders.
Our team of experts includes more than 30 highly trained PhD scientists from around the world with a deep understanding of preclinical research and expertise in the fields of behavior, electrophysiology, bioanalysis, molecular biology and informatics. Our scientists engage with you in the design and execution of your preclinical drug development program using our AAALAC approved animal facilities, proprietary animal models, and extensive capabilities. We pride ourselves on the quality of our work and completing projects on time.
Our state-of-the-art animal vivaria cover over 70,000 square feet and are all AAALAC accredited.
Why 90% of our 160 clients return year after year
Some of PsychoGenics standards and QC procedures are described in the Field Guide above.
PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube®, and PhenoCube® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.
Advantages of PsychoGenics Cube systems include:
PsychoGenics leverages its sophisticated Cube technology platforms and broad capabilities to partner with pharmaceutical, biotechnology and not-for-profit research entities to screen diverse compound libraries and discover valuable new therapies for the CNS market. All partnerships are shared risk arrangements where PsychoGenics shares the risk in drug discovery or lead optimization in exchange for equity and/or milestones payments and royalties.